Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Apr 05, 2023 11:05am
330 Views
Post# 35381025

Looking for a new director

Looking for a new director On March 29, 2023, Richard Gregory, a member of the Board of Directors (the "Board") of ProMIS Neurosciences Inc. (the "Company"), notified the Company of his intent to not stand for re-election to the Board at the Company's 2023 Annual Meeting of Stockholders (the "Annual Meeting") and, as a result, his term as a director of the Company, or on any committee of the Board, will end upon the conclusion of the Annual Meeting. Mr. Gregory's decision to resign from the Board did not result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices. The Company extends its deepest gratitude to Mr. Gregory for his distinguished service to the Board and lasting contributions to the Company.
<< Previous
Bullboard Posts
Next >>